1
|
Bonnet JB, Tournayre S, Anitcheou J, Faivre M, Boegner C, Jalek A, Jullien D, Attalin V, Myzia J, Marty L, Kemba Y, Nocca D, Sultan A, Avignon A. Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery. Obesity (Silver Spring) 2024; 32:50-58. [PMID: 37927153 DOI: 10.1002/oby.23922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 08/27/2023] [Accepted: 08/28/2023] [Indexed: 11/07/2023]
Abstract
OBJECTIVE This retrospective cohort study aimed to assess the effectiveness of semaglutide 2.4 mg in patients with severe obesity (BMI ≥ 40 kg/m2 ) who had previously undergone bariatric surgery (BS) but failed to achieve satisfactory weight loss or experienced weight regain compared with patients without a history of BS with similar BMI. METHODS The authors analyzed data from 129 patients with a BMI ≥ 40 kg/m2 , including 39 with (BS+) and 90 without (BS-) a history of BS. The patients received semaglutide treatment for 24 weeks starting at 0.25 mg/wk and gradually increasing to reach a final dose of 2.4 mg/wk. The treatment outcomes were assessed based on the percentage of weight loss, changes in BMI, and waist circumference. RESULTS Semaglutide treatment resulted in significant 9.1% weight loss in the BS+ group, with no significant difference in weight loss between the BS+ and BS- groups. CONCLUSIONS This study is the first, to the authors' knowledge, to compare the effectiveness of semaglutide treatment in patients with versus those without a history of BS, providing valuable evidence of its efficacy. By focusing on individuals with severe obesity (BMI > 40 kg/m2 and associated comorbidities), it fills a gap in the current literature and highlights the potential of semaglutide 2.4 mg as a treatment option for this specific population.
Collapse
Affiliation(s)
- Jean-Baptiste Bonnet
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France
- Joint Research Unit (UMR) 1302, Desbrest Institute of Epidemiology and Public Health, University of Montpellier, INSERM, Montpellier, France
| | - Sarah Tournayre
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France
| | - Jean Anitcheou
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France
| | - Marion Faivre
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France
| | - Catherine Boegner
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France
| | - Abdulkader Jalek
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France
| | - Dominique Jullien
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France
| | - Vincent Attalin
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France
| | - Justine Myzia
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France
| | - Lucile Marty
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France
| | - Youadigue Kemba
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France
| | - David Nocca
- Institute of Functional Genomics, Joint Research Unit 5203, National Centre for Scientific Research (CNRS) U1191, INSERM, University of Montpellier, Montpellier, France
- Department of Digestive Surgery, University Hospital of Montpellier, Montpellier, France
| | - Ariane Sultan
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France
- PhyMedExp, INSERM U1046, National Centre for Scientific Research (CNRS) Joint Research Unit (UMR) 9214, University of Montpellier, Montpellier, France
| | - Antoine Avignon
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France
- Joint Research Unit (UMR) 1302, Desbrest Institute of Epidemiology and Public Health, University of Montpellier, INSERM, Montpellier, France
| |
Collapse
|
2
|
Dardari D, Potier L, Sultan A, Francois M, M’Bemba J, Bouillet B, Chaillous L, Kessler L, Carlier A, Jalek A, Sbaa A, Orlando L, Bobony E, Detournay B, Kjartansson H, Bjorg Arsaelsdottir R, Baldursson BT, Charpentier G. Intact Fish Skin Graft vs. Standard of Care in Patients with Neuroischaemic Diabetic Foot Ulcers (KereFish Study): An International, Multicentre, Double-Blind, Randomised, Controlled Trial Study Design and Rationale. Medicina (B Aires) 2022; 58:medicina58121775. [PMID: 36556977 PMCID: PMC9786154 DOI: 10.3390/medicina58121775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2022] [Revised: 11/06/2022] [Accepted: 11/24/2022] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND Cell and/or tissue-based wound care products have slowly advanced in the treatment of non-healing ulcers, however, few studies have evaluated the effectiveness of these devices in the management of severe diabetic foot ulcers. METHOD This study (KereFish) is part of a multi-national, multi-centre, randomised, controlled clinical investigation (Odin) with patients suffering from deep diabetic wounds, allowing peripheral artery disease as evaluated by an ankle brachial index equal or higher than 0.6. The study has parallel treatment groups: Group 1 treatment with Kerecis® Omega3 Wound™ versus Group 2 treatment with standard of care. The primary objective is to test the hypothesis that a larger number of severe diabetic ulcers and amputation wounds, including those with moderate arterial disease, will heal in 16 weeks when treated with Kerecis® Omega3 Wound™ than with standard of care. CONCLUSION This study has received the ethics committee approval of each participating country. Inclusion of participants began in March 2020 and ended in July 2022. The first results will be presented in March 2023. The study is registered in ClinicalTrials.gov as Identifier: NCT04537520.
Collapse
Affiliation(s)
- Dured Dardari
- Diabetic Foot Unit, Centre Hospitalier sud Francilien Corbeil Essonnes, 91100 Corbeil-Essonnes, France
- LBEPS, IRBA, Université Evry Paris Saclay, 91025 Evry, France
- Correspondence: ; Tel.: +33-6-61-54-28-09
| | - Louis Potier
- Diabetology Department, CHU Bichat—Claude Bernard, 75018 Paris, France
- Institut Necker-Enfants Malades, Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, 75006 Paris, France
| | - Ariane Sultan
- Diabetology Nutrition Department, CHU Montpelier, Université de Montpellier, 34090 Montpellier, France
- Inserm, CNRS, Phymedexp, CHU de Montpellier, 34090 Montpellier, France
| | | | | | - Benjamin Bouillet
- Department of Endocrinology-Diabetology, Dijon University Hospital, 21000 Dijon, France
- INSERM Unit, LNC-UMR 1231, University of Burgundy, 21078 Dijon, France
| | - Lucy Chaillous
- Department of Endocrinology, Metabolic Diseases and Nutrition, University Hospital of Nante, 44000 Nantes, France
| | - Laurence Kessler
- Department of Diabetology, CHU Strasbourg, 67000 Strasbourg, France
| | - Aurelie Carlier
- Diabetology Department, CHU Bichat—Claude Bernard, 75018 Paris, France
| | - Abdulkader Jalek
- Diabetology Nutrition Department, CHU Montpelier, Université de Montpellier, 34090 Montpellier, France
| | - Ayoub Sbaa
- Department of Diabetology, CHU Strasbourg, 67000 Strasbourg, France
| | - Laurent Orlando
- CERITD (Center for Study and Research for Improvement of the Treatment of Diabetes), Bioparc-Genopole Evry-Corbeil, 91042 Evry, France
| | - Elise Bobony
- CERITD (Center for Study and Research for Improvement of the Treatment of Diabetes), Bioparc-Genopole Evry-Corbeil, 91042 Evry, France
| | - Bruno Detournay
- CEMKA, 43 boulevard du Maréchal Joffre, 92340 Bourg-la-Reine, France
| | | | | | | | - Guillaume Charpentier
- CERITD (Center for Study and Research for Improvement of the Treatment of Diabetes), Bioparc-Genopole Evry-Corbeil, 91042 Evry, France
| |
Collapse
|
3
|
Bonnet J, Macioce V, Jalek A, Bouchdoug K, Elleau C, Gras‐Vidal M, Pochic J, Avignon A, Sultan A. Covid-19 lockdown showed a likely beneficial effect on diabetic foot ulcers. Diabetes Metab Res Rev 2022; 38:e3520. [PMID: 35080096 PMCID: PMC9015270 DOI: 10.1002/dmrr.3520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Revised: 11/29/2021] [Accepted: 01/18/2022] [Indexed: 11/11/2022]
Abstract
AIMS During the Covid-19 epidemic, many countries imposed population lockdown. This study aimed to analyse diabetic foot ulcer (DFU) evolution of outpatients between the lockdown period and 1 month after its end. MATERIALS AND METHODS We conducted a prospective, observational, single-centre study without modification of care. All patients who followed up for a DFU in the study centre between 15 April 2020 and 11 May 2020 were included. The baseline assessment occurred 4 weeks after the beginning of lockdown and the follow-up visit 4-6 weeks after easing of lockdown. The primary analysis was based on the Site, Ischaemia, Neuropathy, Bacterial infection, Area, Depth (SINBAD) classification. RESULTS Twenty-seven patients were included, median 69.4 years, and 25 were followed-up at easing of lockdown. The median SINBAD score was 2 (interquartile range 1; 3) at inclusion and 1 (1; 2) at easing of lockdown, with a mean change of -0.32 (95% confidence interval -0.93; 0.29). Seventy-two percent of the population had a stable or improved score between the two visits. The proportion of patients using off-loading footwear was higher among those whose SINBAD score improved compared to those whose score worsened or remained stable (72%, 44% and 28%, respectively). Diabetes type was linked to DFU prognosis. Five patients (20%) were hospitalized during the follow-up period. CONCLUSION Lockdown appears to have had a positive effect on DFU if patients remain under the care of their expert wound centre. We believe this effect is related to better compliance with offloading. The wide use of tele-medicine seems relevant for the follow-up of DFU.
Collapse
Affiliation(s)
- Jean‐Baptiste Bonnet
- Endocrinology Diabetes DepartmentCHU MontpellierUniversité MontpellierMontpellierFrance
- Desbrest Institute of Epidemiology and Public HealthIDESP UMR UA11 INSERMUniversité MontpellierMontpellierFrance
| | - Valérie Macioce
- Clinical Research and Epidemiology UnitCHU MontpellierUniversité MontpellierMontpellierFrance
| | - Abdulkader Jalek
- Endocrinology Diabetes DepartmentCHU MontpellierUniversité MontpellierMontpellierFrance
- Desbrest Institute of Epidemiology and Public HealthIDESP UMR UA11 INSERMUniversité MontpellierMontpellierFrance
| | - Karim Bouchdoug
- Clinical Research and Epidemiology UnitCHU MontpellierUniversité MontpellierMontpellierFrance
| | - Cécile Elleau
- Endocrinology Diabetes DepartmentCHU MontpellierUniversité MontpellierMontpellierFrance
| | | | - Julie Pochic
- Endocrinology Diabetes DepartmentCHU MontpellierUniversité MontpellierMontpellierFrance
| | - Antoine Avignon
- Endocrinology Diabetes DepartmentCHU MontpellierUniversité MontpellierMontpellierFrance
- Desbrest Institute of Epidemiology and Public HealthIDESP UMR UA11 INSERMUniversité MontpellierMontpellierFrance
| | - Ariane Sultan
- Endocrinology Diabetes DepartmentCHU MontpellierUniversité MontpellierMontpellierFrance
- PhymedexpUniversité de MontpellierInsermCNRSCHRU de MontpellierMontpellierFrance
| |
Collapse
|